Jayastu Senapati

Jayastu Senapati is an Assistant Professor at The University of Texas MD Anderson Cancer Center. His research focuses on hematological malignancies, particularly acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (ALL), with emphasis on lower-intensity triplet therapies, core-binding factor AML, and prognostic biomarkers such as ASXL1 mutations. His recent work includes real-world efficacy of brexucabtagene autoleucel in ALL, integrated genomic analyses of FLAG-based therapy, and microbiome studies differentiating neutropenic fever etiologies. He also investigates bone marrow transplantation, immunology, and pathology, contributing to cancer research through publications in The Lancet Haematology, Blood Cancer Discovery, and Cancer.